[Electrochemotherapy in metastatic melanoma].

Autor:	Kispál M; 1 Országos Onkológiai Intézet, Onkodermatológiai Osztály Budapest, Ráth György u. 7-9., 1122 Magyarország.; 2 Nemzeti Tumorbiológiai Laboratórium Budapest Magyarország., Czirbesz K; 1 Országos Onkológiai Intézet, Onkodermatológiai Osztály Budapest, Ráth György u. 7-9., 1122 Magyarország., Baranyai F; 1 Országos Onkológiai Intézet, Onkodermatológiai Osztály Budapest, Ráth György u. 7-9., 1122 Magyarország., Balatoni T; 1 Országos Onkológiai Intézet, Onkodermatológiai Osztály Budapest, Ráth György u. 7-9., 1122 Magyarország., Liszkay G; 1 Országos Onkológiai Intézet, Onkodermatológiai Osztály Budapest, Ráth György u. 7-9., 1122 Magyarország.; 2 Nemzeti Tumorbiológiai Laboratórium Budapest Magyarország.
Jazyk:	maďarština
Zdroj:	Orvosi hetilap [Orv Hetil] 2023 Sep 03; Vol. 164 (35), pp. 1381-1386. Date of Electronic Publication: 2023 Sep 03 (Print Publication: 2023).
DOI:	10.1556/650.2023.32849
Abstrakt:	Introduction: In metastatic melanoma, despite the increased survival rates with new innovative therapies, therapeutic response is still quite heterogenous, not always durable. In the case of oligoprogression, several additional therapeutic modalities are available such as electrochemotherapy in the local treatment of cutaneous or subcutaneous metastases. Objective: Analysis of our experiences with electrochemotherapy in patients with metastatic melanoma. Method and Results: 23 patients with metastatic melanoma (10 male and 13 female) were treated with electrochemotherapy, between 2016 and 2021 in our Institute. Median age was 74.5 years. The location of metastases varied. 13 of our patients (57%) had metastases on the lower limbs, in 5 cases (22%) metastases were located in the head and neck region, in 4 cases (17%) on the upper limbs, and one (4%) patient received electrochemotherapy for metastases located on the chest. Prior to electrochemotherapy, 7 patients (30%) received chemotherapy, 6 patients (26%) were treated with immunotherapy and 2 patients (9%) received targeted therapy, while electrochemotherapy was first-line treatment for 8 patients (35%). Complete remission was achieved in 12 cases (52%), and partial remission in 6 cases (26%). In 1 case (4%) stable disease was observed, and in 4 patients (35%) progression was detected. We continued the previous systemic therapy which was effective in other localizations after the electrochemotherapy in 8 patients (35%) and in the case of 4 patients (17%) no further systemic therapy was needed. Side effects were observed in 8 patients (35%), 1 had severity of G3. Conclusion: Electrochemotherapy in melanoma results in effective local tumor control, improved quality of life, and survival advantage in most of the patients, with tolerable side effects. Orv Hetil. 2023; 164(35): 1381-1386.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu